Table 3.
Univariate and multivariate Cox regression analysis for OS of patients with stage II/III GC.
| Variables |
No. of patients (n = 3,103) |
Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
|
Hazard ratio (95% CI) |
χ2 | p-value |
Hazard ratio (95% CI) |
χ2 | p-value | ||
| Gender | |||||||
| Male | 2,416 (77.86) | 1.00 | |||||
| Female | 687 (22.14) | 0.95 (0.81–1.11) | 0.45 | 0.503 | |||
| Age (years) | |||||||
| ≤60 | 1,396 (44.99) | 1.00 | 1.00 | ||||
| >60 | 1,707 (55.01) | 1.31 (1.15–1.50) | 15.66 | <0.001 | 1.41 (1.23–1.62) | 23.84 | <0.001 |
| Tumor location | |||||||
| Upper third | 1,480 (47.7) | 1.00 | 1.00 | ||||
| Middle third | 605 (19.5) | 1.14 (0.96–1.36) | 2.12 | 0.145 | 0.89 (0.73–1.09) | 1.21 | 0.271 |
| Lower third | 946 (30.49) | 1.05 (0.90–1.23) | 0.44 | 0.507 | 1.1 (0.93–1.29) | 1.30 | 0.255 |
| Whole stomach | 72 (2.32) | 1.71 (1.18–2.48) | 8.07 | 0.004 | 0.9 (0.6–1.35) | 0.25 | 0.617 |
| SRC proportion | |||||||
| 0% (pure AC) | 2,619 (84.4) | 1.00 | 1.00 | ||||
| 1–50% (mixed-SRC) | 299 (9.64) | 1.29 (1.04–1.61) | 5.29 | 0.021 | 1.30 (1.04–1.62) | 5.17 | 0.023 |
| 51–100% (SRC) | 185 (5.96) | 1.62 (1.27–2.05) | 15.68 | <0.001 | 1.60 (1.26–2.03) | 14.56 | <0.001 |
| Surgical type | |||||||
| Subtotal | 2,351 (75.77) | 1.00 | 1.00 | ||||
| Total | 741 (23.88) | 1.71 (1.48–1.97) | 52.93 | <0.001 | 1.49 (1.25–1.77) | 19.88 | <0.001 |
| Combined organs | 11 (0.35) | 2.66 (1.19–5.94) | 5.71 | 0.017 | 2.16 (0.95–4.91) | 3.37 | 0.067 |
| Borrmann's type | |||||||
| I | 349 (11.42) | 1.00 | 1.00 | ||||
| II | 438 (14.33) | 0.82 (0.62–1.09) | 1.84 | 0.175 | 0.71 (0.53–0.95) | 5.51 | 0.019 |
| III | 1,790 (58.55) | 1.05 (0.85–1.29) | 0.17 | 0.680 | 0.89 (0.72–1.1) | 1.17 | 0.279 |
| IV | 480 (15.7) | 1.67 (1.31–2.12) | 17.28 | <0.001 | 1.15 (0.9–1.48) | 1.22 | 0.270 |
| pT stage | |||||||
| T1 | 48 (1.55) | 1.00 | 1.00 | ||||
| T2 | 229 (7.38) | 4.82 (1.17–19.88) | 4.75 | 0.029 | 4.58 (1.11–18.87) | 4.43 | 0.035 |
| T3 | 833 (26.84) | 5.52 (1.37–22.19) | 5.8 | 0.016 | 5.20 (1.29–20.91) | 5.40 | 0.020 |
| T4 | 1,993 (64.23) | 9.21 (2.30–36.80) | 9.87 | 0.002 | 8.73 (2.18–34.90) | 9.39 | 0.002 |
| pN stage | |||||||
| N0 | 682 (21.98) | 1.00 | 1.00 | ||||
| N1 | 623 (20.08) | 1.37 (1.07–1.76) | 6.08 | 0.014 | 1.19 (0.85–1.67) | 1.05 | 0.306 |
| N2 | 750 (24.17) | 2.06 (1.64–2.58) | 38.61 | <0.001 | 1.59 (1.09–2.31) | 5.79 | 0.016 |
| N3 | 1,048 (33.77) | 3.14 (2.55–3.88) | 115.07 | <0.001 | 1.97 (1.35–2.86) | 12.48 | <0.001 |
| pTNM stage | |||||||
| II | 1,034 (33.32) | 1.00 | 1.00 | ||||
| III | 2,069 (66.68) | 2.72 (2.29–3.22) | 130.21 | <0.001 | 1.41 (1.00–1.98) | 3.83 | 0.050 |
| Lymphovascular invasion | |||||||
| Yes | 574 (18.5) | 1.88 (1.61–2.19) | 65.1 | <0.001 | 1.45 (1.23–1.71) | 20.10 | <0.001 |
| No | 2,529 (81.5) | 1.00 | 1.00 | ||||
| Perineural invasion | |||||||
| Yes | 158 (5.09) | 1.41 (1.07–1.87) | 5.89 | 0.015 | 1.19 (0.89–1.59) | 1.33 | 0.249 |
| No | 2,945 (94.91) | 1.00 | 1.00 | ||||
| Adjuvant therapy | |||||||
| Yes | 2,093 (67.45) | 0.82 (0.62–1.09) | 1.84 | 0.175 | |||
| No | 1,010 (32.55) | 1.00 | |||||
GC, gastric carcinoma; AC, adenocarcinoma; SRC, signet ring cell; CI, confidence interval; pT, pathological tumor; pN, pathological node; pTNM, pathological tumor–node–metastasis.
All p < 0.05 are in bold print.